Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bile acids modulate the interferon signalling pathway.

P Podevin1, O Rosmorduc, F Conti

  • 1INSERM U402, Paris, France.

Hepatology (Baltimore, Md.)
|May 29, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis.

Reumatismo·2020
Same author

TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients.

Journal of immunology research·2019
Same author

Gated liquid scintillator detector for neutron time of flight measurements in a gas-puff Z-pinch experiment.

The Review of scientific instruments·2019
Same author

Anti-D4GDI antibodies activate platelets in vitro: a possible link with thrombocytopenia in primary antiphospholipid syndrome.

Arthritis research & therapy·2019
Same author

CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients.

Lupus·2019
Same author

Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score.

Lupus·2019
Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026
Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026
Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026
See all related articles

Bile acids, common in liver disease, were found to inhibit the interferon (IFN) pathway, reducing antiviral protein production. This may explain why some patients with chronic viral liver diseases do not respond to IFN therapy.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Cholestasis and bile acids are known to inhibit 2', 5' oligoadenylate synthetase (OAS) activity in liver cells.
  • The impact of bile acids on the broader interferon (IFN) pathway activation in liver cells remained unclear.

Purpose of the Study:

  • To investigate the influence of bile acids on interferon (IFN) pathway activation in hepatoma cell lines.
  • To determine the mechanism by which bile acids affect IFN-induced antiviral protein expression.
  • To assess the relevance of these findings at physiological bile acid concentrations.

Main Methods:

  • Hepatoma cell lines (HepG2) and engineered CHO cells expressing human NTCP were treated with bile acids.
  • IFN-induced 2',5' OAS activity, MxA and OAS p100 protein expression (Western blot), STATs tyrosine phosphorylation, and MxA promoter activity were measured.

Related Experiment Videos

  • The role of protein kinase C (PKC) and the Na+-dependent taurocholate cotransporting polypeptide (NTCP) transporter were investigated.

    • Main Results:

    • Bile acids inhibited IFN-induced 2',5' OAS activity and the expression of antiviral proteins MxA and OAS p100 in HepG2 cells.
    • Chenodeoxycholic acid (CDCA) reduced MxA promoter activity by 60% but did not affect STATs tyrosine phosphorylation.
    • Inhibition of the IFN pathway by bile acids was observed at physiological concentrations (12-50 micromol/L) in NTCP-expressing cells.

    Conclusions:

    • Bile acids significantly inhibit the induction of key proteins involved in the antiviral activity of interferon.
    • This inhibitory effect, particularly at physiological concentrations, may contribute to the reduced responsiveness to interferon therapy observed in patients with advanced chronic viral liver diseases.
    • Further research into bile acid modulation of the IFN pathway could lead to improved therapeutic strategies for viral liver diseases.